MX2019011017A - Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii. - Google Patents

Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii.

Info

Publication number
MX2019011017A
MX2019011017A MX2019011017A MX2019011017A MX2019011017A MX 2019011017 A MX2019011017 A MX 2019011017A MX 2019011017 A MX2019011017 A MX 2019011017A MX 2019011017 A MX2019011017 A MX 2019011017A MX 2019011017 A MX2019011017 A MX 2019011017A
Authority
MX
Mexico
Prior art keywords
gastric cancer
anticancer drug
cancer patients
drug compatibility
prognosis
Prior art date
Application number
MX2019011017A
Other languages
English (en)
Inventor
Ho Cheong Jae
Hoon Noh Sung
Min HUH Yong
Ki Kim Hyun
Original Assignee
Novomics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novomics Co Ltd filed Critical Novomics Co Ltd
Publication of MX2019011017A publication Critical patent/MX2019011017A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

La presente invención se refiere a un sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio II y III, y se desarrolla un algoritmo que puede predecir el pronóstico y la respuesta a quimioterapia usando resultados de análisis cuantitativo de niveles de expresión de ARNm de un grupo de genes marcadores relacionados con el pronóstico o la respuesta a quimioterapia y un grupo de genes de referencia en cáncer gástrico avanzado, y puede usarse como información complementaria para determinar un método para tratar a un paciente con cáncer gástrico.
MX2019011017A 2017-03-14 2017-08-11 Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii. MX2019011017A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170032027 2017-03-14
PCT/KR2017/008781 WO2018169145A1 (ko) 2017-03-14 2017-08-11 진행성 위암 환자의 수술 후 예후 또는 항암제 적합성 예측 시스템

Publications (1)

Publication Number Publication Date
MX2019011017A true MX2019011017A (es) 2020-01-20

Family

ID=63523198

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011017A MX2019011017A (es) 2017-03-14 2017-08-11 Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii.

Country Status (17)

Country Link
US (1) US11732304B2 (es)
EP (1) EP3517624A4 (es)
JP (1) JP6864089B2 (es)
KR (2) KR101966642B1 (es)
CN (1) CN110168106B (es)
AU (1) AU2017403899B2 (es)
BR (1) BR112019019022A2 (es)
CA (1) CA3055735C (es)
CL (1) CL2019002633A1 (es)
CO (1) CO2019011359A2 (es)
IL (1) IL269256A (es)
MX (1) MX2019011017A (es)
NZ (1) NZ756580A (es)
PE (1) PE20191482A1 (es)
RU (1) RU2737449C1 (es)
UA (1) UA125590C2 (es)
WO (1) WO2018169145A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA125590C2 (uk) 2017-03-14 2022-04-27 Новомікс Ко., Лтд. Система для передбачення прогнозу та користі від допоміжної хіміотерапії для хворих на рак шлунка ii і iii стадій
US20220267855A1 (en) * 2019-05-03 2022-08-25 Dcgen Co, Ltd. A Method for Predicting Prognosis of Cancer and the Composition Thereof
KR102324294B1 (ko) * 2019-11-19 2021-11-11 서울대학교산학협력단 상피성 난소암 예후 예측 방법 및 장치
KR20220069869A (ko) 2020-11-20 2022-05-27 연세대학교 산학협력단 간암의 예후 예측을 위한 정보 제공 방법
KR102462097B1 (ko) * 2020-12-30 2022-11-02 국립암센터 삼중사중극자 다중반응 모니터링 기반 암 표적치료제 효능 예측
CN113462773A (zh) * 2021-05-19 2021-10-01 山东大学 一种预测胃癌患者生存风险、免疫治疗响应和细胞焦亡诱导剂适用性的标志物及其应用
CN114720687A (zh) * 2022-06-01 2022-07-08 浙江省肿瘤医院 Sfrp4作为胃癌预后标志物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5122713B2 (ja) * 2000-03-27 2013-01-16 トーマス ジェファーソン ユニバーシティ 癌細胞を同定およびターゲティングするための組成物および方法
WO2005007846A1 (ja) 2003-04-25 2005-01-27 Japanese Foundation For Cancer Research 腫瘍細胞の抗癌剤に対する感受性を判定する方法
KR20080006315A (ko) * 2006-07-12 2008-01-16 삼성전자주식회사 전기 영동 장치 및 그의 제조 방법
JP2010514441A (ja) 2006-12-27 2010-05-06 エスエヌユー アールアンドディービー ファウンデーション 内部標準遺伝子を発掘するための遺伝子発現データ処理、分析方法
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
KR101437718B1 (ko) 2010-12-13 2014-09-11 사회복지법인 삼성생명공익재단 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
KR101416147B1 (ko) 2012-07-18 2014-07-09 국립암센터 위암 진단 및 치료를 위한 ａｄｃｙ3의 용도
KR101504817B1 (ko) * 2013-04-05 2015-03-24 연세대학교 산학협력단 국소 진행형 위암에 대한 예후 예측 시스템
WO2015172201A1 (en) * 2014-05-16 2015-11-19 Peter Maccallum Cancer Institute Biomarker of gastric cancer
AU2015343339A1 (en) * 2014-11-03 2017-06-15 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
UA125590C2 (uk) 2017-03-14 2022-04-27 Новомікс Ко., Лтд. Система для передбачення прогнозу та користі від допоміжної хіміотерапії для хворих на рак шлунка ii і iii стадій

Also Published As

Publication number Publication date
CA3055735C (en) 2021-12-14
EP3517624A4 (en) 2020-04-29
CL2019002633A1 (es) 2020-04-03
AU2017403899A1 (en) 2019-09-19
PE20191482A1 (es) 2019-10-18
JP2019537436A (ja) 2019-12-26
BR112019019022A2 (pt) 2020-04-22
CN110168106A (zh) 2019-08-23
CO2019011359A2 (es) 2019-10-31
WO2018169145A1 (ko) 2018-09-20
KR102069043B1 (ko) 2020-01-22
AU2017403899B2 (en) 2021-12-09
KR20180105036A (ko) 2018-09-27
RU2737449C1 (ru) 2020-11-30
UA125590C2 (uk) 2022-04-27
CA3055735A1 (en) 2018-09-20
KR20190024923A (ko) 2019-03-08
US11732304B2 (en) 2023-08-22
EP3517624A1 (en) 2019-07-31
CN110168106B (zh) 2024-02-20
KR101966642B1 (ko) 2019-04-09
JP6864089B2 (ja) 2021-04-21
IL269256A (en) 2019-11-28
NZ756580A (en) 2022-01-28
US20190284637A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
MX2019011017A (es) Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii.
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
BR112016027222A2 (pt) anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
MX2020000604A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
BR112017010788A2 (pt) métodos de identificação de um paciente com câncer e de identificação de um paciente que sofre de câncer que pode beneficiar da administração de um antagonista de vegf, método de tratamento de um paciente com câncer e método para determinar o estágio de câncer de ovário
MX2015010372A (es) Objetivo terapeutico y de diagnostico para el cancer que comprende reactivos que se unen con dll3.
MX365214B (es) Nuevo producto de fusion de fgfr3.
MX2018008169A (es) Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
MX2016002051A (es) Metodos y kits para la subtipificacion molecular de tumores.
CY1122233T1 (el) Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο
PH12014501930A1 (en) Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
EA201790019A1 (ru) Способ выбора персонализированной трехкомпонентной терапии для лечения рака
EP3686290A3 (en) Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
EP3644062A4 (en) METHOD FOR PREDICTING RESPONSE OF SOPHAGE CANCER TO ANTI-ERBB3 ANTIBODY THERAPY, AND KIT
MA40636A (fr) Procédés pour détecter le cancer de la prostate
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
MX2021000133A (es) Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa.
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies